ASP Isotopes Inc.

Company overview

• Core business: Advanced materials company developing a differentiated isotope enrichment platform to strengthen global supply chains for materials used in nuclear medicine, next-generation semiconductors, and nuclear energy.
• Technologies:
  • Aerodynamic Separation Process (ASP) — gas-phase, modular isotope enrichment with no moving parts.
  • Quantum Enrichment (QE) — laser-based isotope enrichment.
• Primary initial targets: Carbon-14 (C-14), Silicon-28 (Si-28), Ytterbium-176 (Yb-176).
• Commercialization status:
  • Commercial production of enriched isotopes began at ASP facilities in Pretoria, South Africa in early 2025.
  • First ASP facility targets C-14 (light isotope enrichment); second, larger facility targets heavier isotopes such as Si-28; third facility (QE) is laser-based for Yb-176 and is producing commercial samples.
  • Targeted shipments: C-14 mid-2026; Si-28 in Q2 2026; Yb-176 mid-2026 to Q3 2026.
• Strategic expansion: Planning additional isotope enrichment facilities in South Africa and other jurisdictions, including Iceland and the United States.

Recent corporate actions and structure

• Acquisitions and investments (completed and contemplated as of early 2026):
  • Renergen acquisition (Jan 2026): Acquired all issued ordinary shares of Renergen, making it a wholly owned subsidiary. Renergen is a South African onshore natural gas explorer and an integrated producer of liquid helium and LNG.
  • Skyline acquisition (completed Aug 2025): QLE acquired a controlling interest in Skyline Builders Group Holding Limited (Hong Kong construction group). Skyline’s operations include Kin Chiu Engineering Limited and Kin Chiu Development Company Limited.
  • PET Labs: Acquired a 51% stake in a South African radiopharmaceutical operations company focused on downstream nuclear medicine and radiopharmacy.
  • East Coast Nuclear Pharmacy (ECNP) acquisition (Oct 2025): Acquired 100% of ECNP to augment radiopharmacy distribution.
• Equity and financing activity (2025–2026):
  • Skyline financings and restructurings included multiple private placements and notes in Feb and Mar 2026, including Series B preferred shares and convertible notes.
  • Private placement proceeds: February 2026 Series B preferred shares (gross proceeds about $31.6 million); March 2026 private placement (gross proceeds about $17.2 million).
  • Renergen, PET Labs, and Skyline transactions expand the company’s asset base across isotopes, radiopharmacy, helium/LNG, and construction.

Operating segments

• Nuclear Fuels
  • Development and potential production of HALEU (5–20% U-235) and Lithium-6 for fusion and advanced fuel cycles.
  • QE and ASP technologies are applicable to uranium enrichment.
  • Collaboration with TerraPower for HALEU facility development; TerraPower arrangements include a loan commitment totaling $22.0 million (potential disbursements of $20.0 million) to partially fund construction of a new uranium enrichment facility in South Africa and supply agreements for HALEU (up to 150 metric tons over 2028–2037), including initial core supply for TerraPower’s Natrium project.
• Specialist Isotopes and Related Services
  • Focus on high-value, low-volume isotopes (C-14, Si-28, Yb-176) and related services.
  • Includes PET Labs and downstream radiopharmacy activities.
• Construction Services
  • Hong Kong civil engineering works through Skyline and affiliates, including roads, drainage, and public works.
  • Skyline operates primarily as a subcontractor and is qualified to act as main contractor.

Customers, contracts and market context

• C-14 tolling and supply:
  • Multi-year tolling arrangement with a Canadian customer for C-14 production with a minimum take-or-pay amount of approximately $2.5 million per year, supported by a bank letter of guarantee.
  • C-14 production process: facility completed in 2023; feedstock converted to methane, enriched to >85% C-14, and planned conversion back to CO2 under the tolling contract.
• Si-28 purchase agreements:
  • Three separate agreements for highly enriched Si-28 with (i) a U.S. semiconductor company, (ii) a global industrial gas company, and (iii) a large U.S. buyer.
  • Ongoing discussions with potential customers for long-term supply agreements for kilogram quantities of Si-28 and larger quantities of Xe-129, Ge-72, Ge-74, Zn-68, Cl-37.
• HALEU and uranium enrichment:
  • TerraPower loan and HALEU supply arrangements described above.
• Helium/LNG and downstream radiopharmacy:
  • Renergen supplies helium and LNG via Phase 1 commercial LNG operations with ongoing gas gathering and tie-in connections.
  • PET Labs and ECNP expand downstream radiopharmacy distribution and services in South Africa.

Employees and facilities

• Employees: 271 full-time as of December 31, 2025, including:
  • 21 in research and development
  • 122 in engineering, construction, and manufacturing
  • 54 in plant operations
  • 74 in general management
• Principal facilities:
  • Corporate headquarters: Dallas, Texas
  • Production, research, and offices: Pretoria, South Africa; Hong Kong
  • Subsidiary operations in the UK and South Africa; Renergen and its Virginia Gas Project operations in South Africa

Intellectual property and regulatory environment

• Intellectual property: Relies on trade secrets and other IP protections. Patent protection in the U.S. for sensitive nuclear technology developed in South Africa is described as potentially unusual; the company assesses patenting on a case-by-case basis.
• Regulatory environment: Subject to U.S. and South African regulations, export controls, sanctions laws (e.g., OFAC), anti-bribery laws (FCPA), and nuclear-related regulatory regimes.
  • South Africa: Isotope enrichment facility governance includes IAEA agreements and NPT obligations; production rights and collaboration with Necsa for potential U-235 enrichment.
  • IAEA and NSG compliance requirements for dual-use technology, and security and access controls at enrichment facilities.

Strategic objectives

• Produce commercial quantities of enriched C-14, Si-28 and Yb-176 at scale to meet anticipated demand.
• Develop HALEU capabilities for HALEU-fueled small modular reactors and other advanced reactor designs, beginning in South Africa with potential activity in the U.S. and UK.
• Grow downstream radiopharmacy and medical isotope capabilities through PET Labs and ECNP.
• Expand helium and LNG operations through Renergen’s Phase 1 commercial activities.

Notable financial and market details

• C-14 tolling contract minimum annual take-or-pay of about $2.5 million.
• Three Si-28 purchase agreements in place.
• TerraPower arrangements include a $22.0 million loan commitment (potentially $20.0 million disbursed) and long-term HALEU supply commitments (up to 150 metric tons over 2028–2037).
• Private placements and financings involving Skyline in 2025–2026 produced gross proceeds of about $31.6 million (Feb 2026) and about $17.2 million (Mar 2026).
• Renergen became a wholly owned subsidiary in January 2026.

Key takeaways

• Core activity: Development and commercialization of ASP and QE isotope enrichment technologies to supply isotopes for medical, semiconductor, and nuclear energy applications, supported by investments in helium/LNG (Renergen) and downstream radiopharmacy (PET Labs, ECNP).
• Production and commercialization: Commercial isotope production began in 2025; shipments of C-14, Si-28, and Yb-176 are targeted for 2026. Active tolling and offtake arrangements are in place.
• Growth strategy: Expansion through acquisitions, financings, and strategic partnerships (including TerraPower) across three operating segments: Nuclear Fuels, Specialist Isotopes and Related Services, and Construction Services.